EBOS Group Limited reported revenue of AUD $13.49 billion for the year ended 30 June 2026, up 9.9 percent from AUD $12.27 billion in the prior year, delivering solid topline growth that reflects the company’s position as a leading distributor in the Australasian healthcare and technology sectors. Earnings before depreciation, amortisation, net finance costs and tax expense reached AUD $598.7 million, up 7.8 percent, while net profit after tax attributable to owners climbed 4.8 percent to AUD $226.1 million.
The growth trajectory appears sound on the surface, but the relationship between EBITDA and EBIT reveals a tightening margin story. While EBITDA grew 7.8 percent, EBIT expanded only 2.4 percent, indicating depreciation and amortisation accelerated to AUD $180.1 million from AUD $146.9 million. This AUD 33 million increase reflects the impact of prior acquisitions on the balance sheet and suggests the company is carrying a heavier intangible asset base. The reconciliation table shows the company recorded AUD $31.9 million in amortisation expense from acquisition purchase price accounting alone, pointing to ongoing integration costs from previous M&A activity.
Earnings per share tells an even more cautious story. Basic EPS moved only 0.1 percent to 109.8 cents despite the 4.8 percent profit growth, as the weighted average share count increased 4.6 percent to 205.1 million shares. This dilution signals that the company has been raising capital or issuing shares for acquisitions, meaning each shareholder now owns a smaller slice of the earnings pie despite the overall profit expansion. For investors focused on per-share value accretion, this is an important read-through.
The underlying earnings adjustments provide crucial context. The company excludes AUD $47.2 million in adjustments from reported EBIT to arrive at underlying EBIT, including AUD $35.6 million in restructuring and site transition costs and AUD $5.2 million in M&A transaction costs. More tellingly, underlying net profit after tax attributable to owners fell 3.1 percent to AUD $249.7 million, despite reported NPAT growing 4.8 percent. This divergence indicates underlying operational performance was softer than the headline numbers suggest, with reported results benefiting from timing of one-time gains and cost impacts.
The company maintained its final dividend at 61.5 NZ cents per share, fully franked to 30 percent, signalling management confidence in cash generation and distribution capacity despite the underlying earnings headwind. The ex-dividend date of 27 August 2026 and payment date of 18 September 2026 are now flagged.
Investors should watch for commentary on the underlying earnings adjustments in the full financial report and management’s guidance on whether restructuring costs are expected to persist or abate in the coming year. The company’s ability to grow EBIT in line with EBITDA growth, and to deliver per-share earnings accretion despite ongoing share dilution, will be key tests of capital allocation discipline.
This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About EBOS Group Limited (ASX: EBO)
EBOS Group Limited is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, hospitals, and healthcare facilities, and also operates an animal health product wholesale and retail business. The company is headquartered in Docklands, Australia and generates the majority of its revenue from pharmaceutical distribution services to community pharmacies and institutional healthcare providers.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
